我們已在上線! 進一步了解
CTIC

CTI BioPharma Corp. (DE) Common Stock

已下市

CTIC已於2023年6月23日下市。

 

關於: CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

員工: 128

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於CTIC的最新新聞文章。

價格圖表採用Lightweight Charts™實作